Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, Sevelamer carbonate (Renvela®) cannot be endorsed for use within NHS Wales for control of hyperphosphataemia in paediatric patients (> 6 years of age and a body surface area (BSA) of > 0.75 m2) with chronic kidney disease. |
||
|
||
Medicine details |
||
| Medicine name | sevelamer carbonate (Renvela®) | |
| Formulation | 2.4 g oral suspension | |
| Reference number | 3550 | |
| Indication | for control of hyperphosphataemia in paediatric patients (> 6 years of age and a body surface area (BSA) of > 0.75 m2) with chronic kidney disease. |
|
| Company | Sanofi-Aventis Ltd | |
| BNF chapter | Nutrition & blood | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Ratification by Welsh Government | 16/10/2017 | |
| Date of issue | 17/10/2017 | |